to_name,company,linkedin_url,type,first_dm,li_title,li_country
Mitsuaki Sekiguchi,"Shionogi & Co., Ltd",http://www.linkedin.com/in/mitsuaki-sekiguchi-7906b218b,JA,"Sekiguchi様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

塩野義製薬様がBD戦略を積極的に展開される中、API R&Dの現場でも文献精査や特許確認など、評価対象案件が増加しているのではないかと拝察いたします。

弊社のIn-Licensing Workflow AIは、オンプレミス環境で候補探索から評価・検討資料自動生成までを一連の業務を自動化し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。実際に、韓国の製薬企業数社にも同様の評価業務でご活用いただいております。

2月16〜17日に東京でお時間をいただけましたら直接ご説明させていただきたく存じます。ご都合の良いお時間帯をお知らせいただけますと幸いです。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。",Team Leader at API R&D Labratory,Japan
Kinichi Imura,"Shionogi & Co., Ltd",http://www.linkedin.com/in/kinichi-imura-81794898,JA,"Imura様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

井村様がイノベーション・インキュベーショングループを統括され、塩野義製薬様の新規事業創出を推進されていることを拝見いたしました。

弊社のIn-Licensing Workflow AIは、案件発掘からデータ整理・評価分析・検討資料自動生成までを一連のプロセスを自動化するオンプレミスAIソリューションです。初期スクリーニング工数を実務負荷の軽減に寄与し、監査証跡とガバナンス対応も標準装備しております。現在、韓国の複数の製薬企業様にも同様の業務でご利用いただいております。

2月16〜17日に東京にてお目にかかれればと存じます。ご都合の良いお時間帯をお知らせいただけますでしょうか。対面が難しい場合はZoomでも対応可能です。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。",,
Tomoko Niimi,"Shionogi & Co., Ltd",http://www.linkedin.com/in/tomoko-niimi-246935246,JA,"Niimi様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

塩野義製薬様はBD案件が加速されている状況かと存じます。案件増加に伴い、初期評価やドキュメント整理の負荷も高まっているのではないでしょうか。

弊社のIn-Licensing Workflow AIは、オンプレミス環境で候補探索から評価・検討資料自動生成までを自動化し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。実際に、韓国の製薬企業様にも同様の評価プロセス効率化でご導入いただいております。

2月16〜17日に東京でお会いできましたら直接ご説明させていただきたく存じます。ご希望のお時間帯をお知らせいただけますと幸いです。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。",,
Mark Hill,"Shionogi & Co., Ltd",http://www.linkedin.com/in/mark-hill-2262a12,EN,"Hi Mark-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build AI workflow tools for pharma in-licensing teams.

With Shionogi's expanding global BD activity, I imagine your Scientific Operations team handles a growing volume of asset evaluations. We have built an on-premise tool that helps automate the manual parts of early screening -- document extraction, data structuring, and evaluation pack assembly -- so teams can focus on the actual science. Several Korean pharma companies use similar workflows with us for their screening processes.

I will be in Tokyo on February 16-17 and would be glad to share a short walkthrough if useful. Zoom works too.

No worries at all if the timing is not right -- happy to reconnect whenever it makes sense.

Best,
Sangyoon Bae
RISORIUS",,
Jared Grobels,Shionogi,http://www.linkedin.com/in/jared-grobels-31888934,EN,"Hi Jared-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build AI workflow tools for pharma BD teams.

With Shionogi actively pursuing in-licensing deals, I imagine the early screening workload -- document review, data extraction, decision pack assembly -- keeps growing. We have built an on-premise tool that automates those manual steps so BD teams can spend more time on evaluation and less on data gathering. We also support several Korean pharma teams with similar screening workflows.

I will be in Tokyo February 16-17. Would be glad to walk through the tool briefly if helpful. Zoom works too.

No worries if the timing is not right -- happy to connect whenever suits.

Best,
Sangyoon Bae
RISORIUS",,
Alistair Phayme,Shionogi,http://www.linkedin.com/in/alistair-phayme1,EN,"Hi Alistair-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build AI workflow tools for pharma in-licensing teams.

Coordinating BD project evaluations across multiple teams at Shionogi likely means a lot of document assembly and manual screening work. We have built an on-premise tool that automates the repetitive parts -- data extraction, document organization, and Decision Pack assembly -- with built-in audit trail. A number of Korean pharmaceutical companies run comparable evaluation workflows with us.

I will be in Tokyo February 16-17 and would be glad to walk through how it works. Zoom also works.

No worries if the timing is not right -- feel free to reach out whenever it makes sense.

Best,
Sangyoon Bae
RISORIUS",,
Takeshi Aoki,"Shionogi & Co., Ltd",http://www.linkedin.com/in/takeshi-aoki-81931836,JA,"Aoki様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

塩野義製薬様がCNS領域を重点的に展開される中、外部候補の科学的評価にも多くのリソースを割かれているのではと拝察いたします。

弊社のIn-Licensing Workflow AIは、文書からの構造化データ抽出・標準化評価・リスクギャップ分析までをオンプレミス環境で自動化し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。実際に、韓国の製薬企業数社にも同様の評価自動化でご利用いただいている実績がございます。

2月16〜17日に東京でお会いできましたら直接ご説明させていただきたく存じます。ご希望のお時間帯をお知らせいただけますと幸いです。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。","CNS Scientific Lead, Medical Affairs at Shionogi & Co., Ltd.",Japan
Yasuyuki Ariyasu,"Shionogi & Co., Ltd",http://www.linkedin.com/in/yasuyuki-ariyasu-6902705,JA,"Ariyasu様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

塩野義製薬様がパイプライン強化を加速される中、臨床開発部門でも治験計画の検討や評価対象案件が増えていらっしゃるのではと存じます。

弊社のIn-Licensing Workflow AIは、候補探索からデータ整理・評価分析・検討資料自動生成までを一連の業務を自動化し、初期スクリーニング工数を実務負荷の軽減に寄与するオンプレミスソリューションです。韓国の複数の製薬企業様にも同様の評価業務効率化でお役立ていただいております。

2月16〜17日に東京でご説明の機会をいただけましたら幸いです。ご都合の良いお時間帯をお知らせいただけますと幸いです。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。","Clinical Development at SHIONOGI & CO., LTD.",Japan
Wenjing Zhao,Shionogi,http://www.linkedin.com/in/wjnzhao,EN,"Hi Wenjing-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build AI workflow tools for pharma BD assessment teams.

Leading BD Assessment at Shionogi, you are likely handling a growing volume of in-licensing evaluations. We have built an on-premise tool that automates the manual parts of early screening -- data extraction, document structuring, and Decision Pack generation -- so assessment teams can focus on strategic evaluation. We work with Korean pharma companies on comparable assessment processes as well.

I will be in Tokyo February 16-17 and would welcome a quick chat if relevant. Zoom works too.

No worries if the timing is not right -- happy to reconnect whenever it makes sense.

Best,
Sangyoon Bae
RISORIUS",,
Masaaki Sasaoka,"Shionogi & Co., Ltd",http://www.linkedin.com/in/masaaki-sasaoka-b85b4547,JA,"Sasaoka様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

塩野義製薬様のBD部門テクノロジーグループにて、案件の技術評価を担当されている笹岡様にご連絡いたしました。大型案件が続く中、技術デューデリジェンスの負荷も増大されているのではないでしょうか。

弊社のIn-Licensing Workflow AIは、オンプレミス環境で文書の構造化データ抽出・リスクギャップ分析・検討資料自動生成を実現し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。実際に、韓国の製薬企業様にも同様の候補評価業務でご活用いただいている実績がございます。

2月16〜17日に東京でお会いできましたら幸いです。ご都合の良いお時間帯をお知らせいただけますと幸いです。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。","Senior Manager, Business Development - Shionogi & Co., Ltd",Japan
Hiroki Ozasa,"Shionogi & Co., Ltd",http://www.linkedin.com/in/hiroki-ozasa-498970217,JA,"Ozasa様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

塩野義製薬様がBD案件を積極展開されている中、日々の案件スクリーニング業務も相当な量になっているのではと拝察いたします。

弊社のIn-Licensing Workflow AIは、案件発掘から評価分析・検討資料自動生成までをオンプレミスで自動化し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。監査証跡機能も標準搭載です。実際に、韓国の製薬企業数社にも同様のワークフロー効率化でご導入いただいております。

2月16〜17日に東京でお時間をいただけましたら直接ご説明させていただきたく存じます。ご希望の時間帯をお知らせいただけますと幸いです。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。",Business Development,Japan
Keisuke Kusumoto,"Shionogi & Co., Ltd",http://www.linkedin.com/in/keisuke-kusumoto-41b2ba1a0,JA,"Kusumoto様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

楠本様がCVCおよび経営企画部門を統括され、塩野義製薬様の戦略的投資を推進されていることを拝見いたしました。ポートフォリオ戦略の観点から、投資案件の評価・分析プロセスも高度化が求められているのではないでしょうか。

弊社のIn-Licensing Workflow AIは、オンプレミス環境で案件発掘からデータ構造化・リスク分析・検討資料自動生成までを一連の業務を自動化し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。実際に、韓国の製薬企業数社にも同様の業務自動化でご利用いただいております。

2月16〜17日に東京でお目にかかれませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも対応可能です。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。",,
Masahide Fujita,"Shionogi & Co., Ltd",http://www.linkedin.com/in/masahide-fujita-3203829a,JA,"Fujita様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

藤田様がライセンシング・トランザクションユニットを統括され、塩野義製薬様のインライセンス戦略を牽引されていることを存じております。トランザクション案件が加速する中、評価プロセスの効率化が一層重要になっているかと存じます。

弊社のIn-Licensing Workflow AIは、案件発掘から検討資料自動生成までをオンプレミスで自動化し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。構造化データ抽出と標準化評価フレームワークを備え、監査証跡も完備しております。韓国の製薬企業様にも同様のスクリーニング効率化で協業実績がございます。

2月16〜17日に東京でお目にかかれませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも対応可能です。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。",,
Toshiyuki Asaki,"Shionogi & Co., Ltd",http://www.linkedin.com/in/toshiyuki-asaki-9ba45b78,JA,"Asaki様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

浅木様が執行役員SVPとして創薬研究本部を統括されている中、塩野義製薬様はCNS領域や感染症領域で積極的に外部候補獲得を推進されていると拝察いたします。

弊社のIn-Licensing Workflow AIは、外部候補の発掘から構造化データ抽出・リスクギャップ分析・検討資料自動生成までをオンプレミスで一連の業務を自動化し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。韓国の複数の製薬企業様にも同様の業務でご採用いただいている実績がございます。

2月16〜17日に東京でお目にかかれませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも承ります。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。",제약연구 본부장,Japan
Masatomo Rokushima,"Shionogi & Co., Ltd",http://www.linkedin.com/in/masatomo-rokushima-587571152,JA,"Rokushima様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

塩野義製薬様が感染症領域を中核に据え、ワクチンR&Dを重点的に推進される中、六島様のラボでも外部技術や候補の評価案件が増加されているのではと拝察いたします。

弊社のIn-Licensing Workflow AIは、候補発掘からデータ構造化・評価分析・検討資料自動生成までをオンプレミス環境で自動化し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。ガバナンスコンプライアンスと監査証跡も標準装備です。実際に、韓国の製薬企業数社にも同様の評価業務効率化でご利用いただいております。

2月16〜17日に東京でお会いできませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも対応可能です。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。","Senior Director, Vaccine R&D Laboratory at Shionogi & Co., Ltd.",Japan
Teruhiko Taishi,"Shionogi & Co., Ltd",http://www.linkedin.com/in/teruhiko-taishi-a770a623a,JA,"Taishi様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

大石様が製薬開発プロジェクトマネジメントを統括される中、塩野義製薬様のパイプライン拡大に伴い、評価・意思決定プロセスの複雑性も増しているのではないでしょうか。

弊社のIn-Licensing Workflow AIは、候補探索から構造化データ抽出・標準化評価・検討資料自動生成までを一連の業務を自動化するオンプレミスソリューションです。初期スクリーニング工数を実務負荷の軽減に寄与し、部門横断の評価チームの効率化に貢献いたします。現在、韓国の製薬企業様にも同様の評価業務プロセスでご導入いただいております。

2月16〜17日に東京でお目にかかれませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも承ります。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。",Senior Director of Pharmaceutical Development Project Management,Japan
John Keller,"Shionogi & Co., Ltd",http://www.linkedin.com/in/john-keller-2aa13a112,EN,"Hi John-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build AI workflow tools for pharma in-licensing teams.

Overseeing Shionogi's R&D pipeline, you likely see the volume of assets to evaluate growing steadily. We have built an on-premise tool that automates the manual parts of early screening -- data extraction, document structuring, and Decision Pack generation -- so R&D evaluators can focus on the decisions that matter. Several Korean pharma companies rely on similar workflows with us for their pipeline evaluations.

I will be in Tokyo February 16-17 and would welcome a short conversation if useful. Zoom works too.

No worries at all if the timing is not right -- happy to reconnect whenever it makes sense.

Best,
Sangyoon Bae
RISORIUS","Director of the Board, SVP, R&D, Shionogi & Co., Ltd.",Japan
Keiichi Ono,"Shionogi & Co., Ltd",http://www.linkedin.com/in/keiichi-ono-061851145,JA,"Ono様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

塩野義製薬様が感染症領域を中核戦略に据え、ワクチン開発を積極的に推進される中、小野様の処方R&D部門でも外部技術や候補化合物の評価業務が増えているのではないかと拝察いたします。

弊社のIn-Licensing Workflow AIは、文書からの構造化データ抽出・標準化評価・リスクギャップ分析・検討資料自動生成をオンプレミスで実現し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。実際に、韓国の複数の製薬企業様にも同様のデータ抽出・評価業務でご利用いただいております。

2月16〜17日に東京でお時間をいただけましたら直接ご説明させていただきたく存じます。ご希望のお時間帯をお知らせいただけますと幸いです。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。",,
Soichi Shiono,"Shionogi & Co., Ltd",http://www.linkedin.com/in/soichi-shiono-9655a917,EN,"Hi Shiono-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build AI workflow tools for pharma in-licensing teams.

Heading Alliance Management and Investment at Shionogi, you are likely balancing existing partnerships with evaluating new in-licensing opportunities. We have built an on-premise tool that automates the manual parts of screening -- data extraction, document structuring, and Decision Pack generation -- to help free up time for higher-value evaluation work. We also support Korean pharma teams managing similar alliance evaluation workflows.

I will be in Tokyo February 16-17 and would be glad to walk through the tool briefly. Zoom works too.

No worries if the timing is not right -- happy to reconnect whenever it suits.

Best,
Sangyoon Bae
RISORIUS",,
Masashi Deguchi,"Shionogi & Co., Ltd",http://www.linkedin.com/in/masashi-deguchi-478550105,JA,"Deguchi様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

出口様が執行役員SVPとしてDX推進本部を統括され、塩野義製薬様全社のデジタルトランスフォーメーションを牽引されていることを拝見いたしました。

弊社のIn-Licensing Workflow AIは、インライセンスプロセス全体（候補探索・データ構造化・評価分析・検討資料自動生成）をオンプレミスで自動化するAIソリューションです。初期スクリーニング工数を実務負荷の軽減に寄与し、監査証跡・ガバナンスコンプライアンスも完備しております。システム連携やセキュリティの観点からも安心してご導入いただけます。韓国の製薬企業数社にも同様の評価プロセス効率化でご採用いただいております。DX推進施策の一環として、BD部門への展開をご検討いただけませんでしょうか。

2月16〜17日に東京でお目にかかれれば幸いです。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも承ります。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。",,
Ken-Ichi Kusakabe,"Shionogi & Co., Ltd",http://www.linkedin.com/in/ken-ichi-kusakabe-b08219160,JA,"Kusakabe様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

日下部様がニューロサイエンス・ケミストリー部門を統括される中、塩野義製薬様は選択的CNSプログラムを積極的に推進されていると拝察いたします。外部候補の科学的評価にも大きなリソースが必要ではないでしょうか。

弊社のIn-Licensing Workflow AIは、オンプレミス環境で文書の構造化データ抽出・標準化評価・リスクギャップ分析・検討資料自動生成を実現し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。韓国の製薬企業数社とも同様の評価ワークフロー自動化で協業しております。

2月16〜17日に東京でお会いできませんでしょうか。ご都合の良いお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも承ります。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。","Director, Head of Neuroscience Chemistry at Shionogi & Co., Ltd",Japan
Mitsuru Yamamoto,"Shionogi & Co., Ltd",http://www.linkedin.com/in/mitsuru-yamamoto-3554a2180,JA,"Yamamoto様

お繋がりいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

塩野義製薬様はBD案件を積極的に展開されており、現場でのスクリーニングやドキュメント整理にも大きな負荷がかかっているのではないでしょうか。

弊社のIn-Licensing Workflow AIは、案件発掘から評価・検討資料自動生成までをオンプレミスで自動化し、初期スクリーニング工数を実務負荷の軽減に寄与いたします。実際に、韓国の複数の製薬企業様にも同様の評価効率化で協業させていただいております。

2月16〜17日に東京でお時間をいただけましたら直接ご説明させていただきたく存じます。ご希望のお時間帯をお知らせいただけますと幸いです。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。",사업개발,Japan
Yuji Kando,"Shionogi & Co., Ltd",http://www.linkedin.com/in/yuji-kando-71a3996,EN,"Hi Kando-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build AI workflow tools for pharma in-licensing teams.

As Director of In-Licensing at Shionogi, you know firsthand how much manual work goes into early-stage screening -- gathering documents, extracting data, building evaluation packs. We have built an on-premise tool that automates those steps, so in-licensing teams can focus on the evaluation itself. In fact, Korean pharma in-licensing teams also use similar workflows with us.

I will be in Tokyo February 16-17 and would be glad to share a quick walkthrough if relevant. Zoom works too.

No worries if the timing is not right -- happy to connect whenever suits.

Best,
Sangyoon Bae
RISORIUS","In-Licensing, BD Director",Japan
Junichi Onuma,Aculys Pharma,http://www.linkedin.com/in/junichi-onuma-naga270,EN,"Hi Onuma-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build AI workflow tools for pharma in-licensing teams.

With pitolisant's NDA progress and Aculys's growing pipeline, I imagine your clinical development team is spending more time screening overseas-approved assets for Japan regulatory fit. We have built an on-premise tool that automates the manual parts of that screening -- data extraction, document structuring, and evaluation pack generation. We work with several Korean pharmaceutical companies on similar screening processes.

I will be in Tokyo February 16-17 and would be glad to share a short walkthrough if useful. Zoom works too.

No worries if the timing is not right -- happy to reconnect whenever it makes sense.

Best,
Sangyoon Bae
RISORIUS",임상개발부 부장,Japan
Masaru Matsuoka,Aculys Pharma,http://www.linkedin.com/in/masaru-matsuoka-30b355256,EN,"Hi Matsuoka-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build AI workflow tools for pharma in-licensing teams.

With Aculys focused on bringing overseas-approved CNS therapies to Japan, I imagine your medical team spends considerable time assembling clinical and regulatory data for each candidate. We have built an on-premise tool that automates those manual steps -- data extraction, document structuring, and standardized evaluation -- so medical teams can focus on the clinical assessment. A number of Korean pharma companies use similar evaluation workflows with us.

I will be in Tokyo February 16-17 and would welcome a quick chat if relevant. Zoom works too.

No worries if the timing is not right -- happy to connect whenever suits.

Best,
Sangyoon Bae
RISORIUS",,
Hidemasa Tanigaki,Aculys Pharma,http://www.linkedin.com/in/hidemasa-tanigaki-29aa63126,EN,"Hi Tanigaki-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build AI workflow tools for pharma in-licensing teams.

With Aculys's strategy centered on licensing overseas-approved CNS therapies into Japan, in-licensing evaluation is a core and growing workload. We have built an on-premise tool that automates the manual parts of early screening -- document organization, data extraction, and Decision Pack assembly -- so teams can spend more time on the evaluations themselves. We also support several Korean pharma teams with comparable in-licensing workflows.

I will be in Tokyo February 16-17 and would be glad to walk through how it works. Zoom also works.

No worries at all if the timing is not right -- happy to reconnect whenever it makes sense.

Best,
Sangyoon Bae
RISORIUS",Chief Executive Officer and President,Japan
Kazunori Shibata,Aculys Pharma,http://www.linkedin.com/in/kazunori-shibata-3384b9157,EN,"Hi Shibata-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build AI workflow tools for pharma in-licensing teams.

As Aculys grows its in-licensing pipeline, keeping governance and compliance tight across more evaluations is no small task. We have built an on-premise tool that automates document organization and Decision Pack generation while keeping full audit trail and traceability built in -- designed specifically for teams where compliance matters. Notably, Korean pharma companies with similar compliance requirements also use the tool.

I will be in Tokyo February 16-17 and would welcome a quick conversation if relevant. Zoom works too.

No worries if the timing is not right -- happy to reconnect whenever it suits.

Best,
Sangyoon Bae
RISORIUS",Head of Corporate Administration,Japan
Takayuki Hara,Nobelpharma Co. LTD,http://www.linkedin.com/in/takayuki-hara-049210197,JA,"Hara様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

ノーベルファーマ様は希少疾病・アンメットメディカルニーズに注力され、メラトベル錠やノベルジン顆粒など着実にパイプラインを拡大されていると拝察いたします。

海外候補の日本向け導入評価において、資料整理・データ抽出・リスク分析に多くの工数がかかっていないでしょうか。

弊社のイン・ライセンシングワークフローAIは、候補探索から検討資料自動生成まで一連の業務を自動化し、実務負荷の軽減に寄与するオンプレミス型ソリューションです。監査証跡・ガバナンス対応も標準装備しております。現在、韓国の製薬企業様数社にも同様の業務効率化でご活用いただいております。

2月16日・17日に東京におりますので、30分ほどお時間を頂戴できますと幸いです。対面が難しい場合はZoomでも対応可能です。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。

ペ・サンユン",Head,Japan
Katsu Endo,Nobelpharma Co. LTD,http://www.linkedin.com/in/katsu-endo-b2b67512,JA,"Endo様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

ノーベルファーマ様は医薬品に加え医療機器分野でも積極的に導入を推進されており、評価対象の多様化に伴い、部門横断での意思決定プロセスがますます重要になられているかと存じます。

現在、導入候補の評価資料を手作業で整理・分析されている場合、標準化されたフレームワークがあれば意思決定のスピードと精度が大きく変わります。

弊社のイン・ライセンシングワークフローAIは、構造化データ抽出・標準評価フレームワーク・リスク分析を自動化し、実務負荷の軽減に寄与します。オンプレミス対応で監査証跡も完備です。実際に、韓国の製薬企業数社にも同様の評価業務プロセスで協業実績がございます。

2月16〜17日に東京へ参りますので、ぜひ対面でご説明の機会を頂けますと幸いです。Zoomでも可能です。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。

ペ・サンユン","Executive Officer, Head of Medical Device Division",Japan
Kusayanagi,Nobelpharma Co. LTD,http://www.linkedin.com/in/kusayanagi-tomoe-265a9687,JA,"Kusayanagi様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

ノーベルファーマ様のR&D部門では、希少疾病領域の導入候補について、膨大な文献・データの精査に多大な時間を費やされているのではないでしょうか。

弊社のイン・ライセンシングワークフローAIは、文書からの構造化データ抽出、標準化された評価、リスク・ギャップ分析までを自動化し、実務負荷の軽減に寄与するオンプレミス型ツールです。韓国の製薬企業数社とも同様の評価効率化業務で協業させていただいております。

2月16〜17日に東京におりますので、直接ご説明の機会を頂ければ幸いです。Zoomも対応可能です。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。

ペ・サンユン",R&D Division,Japan
Tokuhisa Yamato,Kissei Pharmaceutical Co Ltd,http://www.linkedin.com/in/tokuhisa-yamato-137a3883,JA,"Yamato様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

キッセイ薬品様はViridian社とのTED案件（7,000万ドル）やBoston OIオフィス設立など、イン・ライセンシングを積極的に推進されていると拝察いたします。

海外案件の増加に伴い、臨床プロジェクト管理の観点から、候補の評価・分析業務の効率化が重要課題ではないでしょうか。

弊社のイン・ライセンシングワークフローAIは、候補探索から検討資料自動生成まで一連のプロセスを自動化し、実務負荷の軽減に寄与します。オンプレミス対応・監査証跡完備のソリューションです。実際に、韓国の製薬企業様数社にも同様の業務プロセス効率化でご活用いただいております。

2月16〜17日に東京本社付近へ参ります。30分ほどお時間を頂戴できますでしょうか。対面が難しい場合はZoomでも可能です。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。

ペ・サンユン","Senior Director, Clinical Projects Management",Japan
Tomoyuki Terayama,Kissei Pharmaceutical Co Ltd,http://www.linkedin.com/in/tomoyuki-terayama-75b1b6153,JA,"Terayama様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

キッセイ薬品様はViridian社TED案件やBoston OIオフィスなど、イン・ライセンシングを事業の柱として強化されているかと存じます。BD部門のご担当として、候補探索から社内評価資料の作成まで、幅広い業務を担われているのではないでしょうか。

弊社のイン・ライセンシングワークフローAIは、候補探索・データ整理・評価分析・検討資料生成を自動化し、実務負荷の軽減に寄与するオンプレミス型ソリューションです。実際に、韓国の製薬企業数社にも同様の評価業務でご活用いただいております。

2月16〜17日に東京へ参ります。お時間を頂ければ直接ご説明いたします。Zoomも対応可能です。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。

ペ・サンユン","Manager, Business Development",Japan
Hidetoshi Suzuki,Kissei Pharmaceutical Co Ltd,,JA,"Suzuki様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。創業者を務めております。

キッセイ薬品様はViridian社との大型提携やBoston拠点の設立など、グローバルなイン・ライセンシング体制を構築されていると拝察いたします。

BD部門では、海外候補資産の文献精査・データ整理・評価レポート作成に多くの時間を費やされていませんか。これらが自動化されれば、より戦略的な案件判断に集中いただけます。

弊社のワークフローAIは、構造化データ抽出から検討資料生成まで一連の業務を自動化し、実務負荷の軽減に寄与します。現在、韓国の複数の製薬企業様にも同様の業務でご利用いただいております。

2月16〜17日に東京へ参りますので、直接お話しする機会を頂ければ幸いです。Zoomも対応可能です。

ご不要でしたらご放念くださいませ。何卒よろしくお願い申し上げます。

ペ・サンユン",Business Development Department,Japan
Jo Longland,Nxera Pharma,http://www.linkedin.com/in/jolongland,EN,"Hi Longland-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for pharma licensing workflows.

With Nxera running 7 active pipeline programs, I thought our In-Licensing Workflow AI might be relevant to your team. It automates candidate screening, document extraction, and Decision Pack generation, and is designed to reduce the manual workload involved in evaluating new opportunities. Several Korean pharma companies run similar evaluation workflows with us.

I will be in Tokyo February 16–17 if a short conversation would be useful. Zoom works too.

Looking forward to hearing from you.",R&D Project Manager,United Kingdom
Sital Kotecha,Nxera Pharma,http://www.linkedin.com/in/sital-kotecha-70916b,EN,"Hi Kotecha-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma licensing evaluation workflows.

Given your role leading IT at Nxera, I thought our In-Licensing Workflow AI might be worth a brief conversation. It is fully on-premise with no cloud dependencies, includes audit trail and governance compliance, and automates document extraction and Decision Pack generation. We also work with Korean pharma IT teams on similar on-premise deployments.

I will be in Tokyo February 16–17. Happy to meet or do a short Zoom call if that works better.

Looking forward to hearing from you.",Global Head of IT - Business Applications & Corporate Systems,United Kingdom
Lise Peronnaud,Nxera Pharma,http://www.linkedin.com/in/lise-peronnaud-9424976,EN,"Hi Peronnaud-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma licensing workflows.

With Nxera's portfolio covering discovery through development, I thought our In-Licensing Workflow AI might be useful. It automates candidate screening, structured data extraction, and Decision Pack generation — designed to reduce the manual effort in evaluating licensing opportunities. We support several Korean pharmaceutical companies with similar portfolio evaluation workflows.

I will be in Tokyo February 16–17 if a brief chat would be helpful. Zoom works too.

Looking forward to hearing from you.",R&D Project & Portfolio Manager - Drug Discovery and Development,United Kingdom
Marcus Messenger,Nxera Pharma,http://www.linkedin.com/in/marcus-messenger-b395982,EN,"Hi Messenger-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma business development workflows.

With Nxera running 7 pipeline programs and an active licensing model, I thought our In-Licensing Workflow AI might be relevant. It automates candidate screening, document extraction, and Decision Pack generation — designed to reduce the manual workload in deal evaluation. A number of Korean pharma BD teams use similar workflows with us.

I will be in Tokyo February 16–17. Happy to meet or arrange a Zoom call if that is easier.

Looking forward to hearing from you.",Head of Business Development,United Kingdom
Kenshi Hironaka,Nxera Pharma,http://www.linkedin.com/in/kenshi-hironaka,EN,"Hi Hironaka-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma licensing workflows.

Given your role in business applications at Nxera, I thought our In-Licensing Workflow AI might be worth discussing from a technical perspective. It is fully on-premise with no external data transfer, includes audit trail and governance compliance, and automates document extraction and evaluation analysis. Notably, Korean pharma companies also run the tool on-premise with similar technical requirements.

I will be in Tokyo February 16–17. Happy to walk through the architecture in person or via Zoom.

Looking forward to hearing from you.",Lead Manager - Business Applications and Corporate Systems,Japan
Yen Chen,PeptiDream,http://www.linkedin.com/in/ychen4,EN,"Hi Chen-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma licensing and alliance evaluation workflows.

With PeptiDream managing a broad alliance portfolio, I thought our In-Licensing Workflow AI might be relevant to your team. It automates candidate screening, structured data extraction, and Decision Pack generation — designed to reduce the manual effort in evaluating partnership opportunities. We also work with several Korean pharma companies on comparable alliance evaluation processes.

I will be in Tokyo February 16–17 if a brief meeting would be useful. Zoom works too.

Looking forward to hearing from you.",Head of Business Planning & Alliance Management,Japan
Makoto Jitsuoka,PeptiDream,http://www.linkedin.com/in/makoto-jitsuoka-4646b215a,EN,"Hi Jitsuoka-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma evaluation workflows.

With PeptiDream's platform partnerships generating ongoing R&D evaluation needs, I thought our In-Licensing Workflow AI might be relevant. It automates document extraction, evaluation analysis, and Decision Pack generation — designed to reduce the manual screening time that R&D teams typically carry. Several Korean pharmaceutical R&D teams use similar workflows with us.

I will be in Tokyo February 16–17 if a brief conversation would be helpful. Zoom works too.

Looking forward to hearing from you.","Associate Director, R&D Department",Japan
Christian Cunningham,PeptiDream,http://www.linkedin.com/in/christian-cunningham-a32a5117,EN,"Hi Cunningham-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma licensing workflows.

As CSO at PeptiDream, I imagine partnership evaluation is a continuous part of your team's workload. Our In-Licensing Workflow AI automates candidate screening, data extraction, and Decision Pack generation — designed to reduce the manual effort involved in assessing new opportunities. We work with Korean pharma companies on similar partnership evaluation workflows.

I will be in Tokyo February 16–17. Happy to meet or arrange a Zoom call if that works better.

Looking forward to hearing from you.",Chief Scientific Officer,Japan
Yasushi Yoshimi,Meiji Seika Kaisha Ltd,http://www.linkedin.com/in/yasushi-yoshimi-56103564,EN,"Hi Yoshimi-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma licensing workflows.

With Meiji Seika expanding its open innovation strategy, I thought our In-Licensing Workflow AI might be relevant. It automates candidate screening, data extraction, and Decision Pack generation — designed to reduce the manual effort in evaluating external assets. In fact, Korean pharma companies with similar open innovation models also use the tool.

I will be in Tokyo February 16–17 if a brief conversation would be helpful. Zoom works too.

Looking forward to hearing from you.",Branch Office Manager,Japan
Toshiaki Nagasato,Meiji Seika Kaisha Ltd,http://www.linkedin.com/in/toshiaki-nagasato-426a4320,EN,"Hi Nagasato-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma evaluation workflows.

With Meiji Seika pursuing its open innovation strategy through partnerships like MBC BioLabs, I thought our In-Licensing Workflow AI might be useful. It automates document extraction, evaluation analysis, and Decision Pack generation — designed to reduce the manual screening effort for external asset candidates. We also support several Korean pharma teams with similar external asset screening workflows.

I will be in Tokyo February 16–17. Happy to meet or do a Zoom call if that works better.

Looking forward to hearing from you.",Deputy Director Bioscience Labs.,Japan
Hiroyuki Hayashi,Meiji Seika Kaisha Ltd,http://www.linkedin.com/in/hiroyuki-hayashi-19288267,EN,"Hi Hayashi-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma licensing workflows.

With Meiji Seika's open innovation strategy expanding, I thought our In-Licensing Workflow AI might be relevant to your Research Institute. It automates candidate screening, data extraction, and Decision Pack generation — designed to reduce the manual work in evaluating external assets. A number of Korean pharma research teams run comparable evaluation workflows with us.

I will be in Tokyo February 16–17 if a brief conversation would be helpful. Zoom works too.

Looking forward to hearing from you.",Research Institute Director,Japan
Hirotake Ishida,RaQualia Pharma Inc,http://www.linkedin.com/in/hirotake-ishida-3a7613196,EN,"Hi Ishida-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma licensing evaluation workflows.

With tegoprazan's FDA filing progressing, I thought our In-Licensing Workflow AI might be relevant to RaQualia's Drug Discovery Innovation Group. It automates candidate screening, data extraction, and Decision Pack generation — designed to reduce the manual evaluation workload. Several Korean pharma discovery teams use similar evaluation workflows with us.

I will be in Tokyo February 16–17 if a brief meeting would be useful. Zoom works too.

Looking forward to hearing from you.",Senior Scientist/ Drug Discovery Innovation Group/ Biologist,Japan
Kiyoshi Kawamura,RaQualia Pharma Inc,http://www.linkedin.com/in/kiyoshi-kawamura-76a937148,EN,"Hi Kawamura-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma licensing workflows.

With tegoprazan's FDA filing progressing and RaQualia's pipeline activity growing, I thought our In-Licensing Workflow AI might be relevant. It automates candidate screening, data extraction, and Decision Pack generation — designed to reduce the manual effort in evaluating licensing opportunities. We also work with Korean pharma companies on comparable licensing evaluation processes.

I will be in Tokyo February 16–17. Happy to meet or arrange a Zoom call.

Looking forward to hearing from you.","VP, Head of Research and Development",Japan
Toshiyuki Saito,RaQualia Pharma Inc,http://www.linkedin.com/in/toshiyuki-saito-863015181,EN,"Hi Saito-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma BD and licensing workflows.

With RaQualia managing both out-licensing and incoming evaluations, I thought our In-Licensing Workflow AI might be relevant to your work. It automates document extraction, evaluation analysis, and Decision Pack generation — designed to reduce the manual effort in deal screening. In fact, Korean pharma BD teams also use the tool for similar deal evaluation workflows.

I will be in Tokyo February 16–17 if a brief conversation would be useful. Zoom works too.

Looking forward to hearing from you.","Vice President, Head of Business Development & Intellectual Property",Japan
Yusuke Ohno,RaQualia Pharma Inc,http://www.linkedin.com/in/yusuke-ohno-46193258,EN,"Hi Ohno-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma evaluation workflows.

With tegoprazan's FDA filing progressing and RaQualia's pipeline moving forward, I thought our In-Licensing Workflow AI might be relevant to your research planning work. It automates data extraction, evaluation analysis, and Decision Pack generation — designed to reduce manual screening time. We support several Korean pharma research planning teams with similar workflows.

I will be in Tokyo February 16–17. Happy to meet or do a Zoom call if that works better.

Looking forward to hearing from you.",Research Planning,Japan
Annamaria Muroni,JCR Pharmaceuticals,http://www.linkedin.com/in/annamaria-muroni-83a058115,EN,"Hi Muroni-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for pharma licensing workflows.

I saw JCR's recent Acumen partnership and thought our work might be relevant to your clinical operations team. When licensing activity picks up, the evaluation prep — pulling documents, structuring data, assembling decision materials — tends to pile up quickly.

Our In-Licensing Workflow AI is designed to help reduce that manual effort. It handles document extraction, candidate evaluation, and Decision Pack generation, all on-premise with audit trail. Several Korean pharma companies use similar clinical evaluation workflows with us.

I'll be in Tokyo February 16–17 if a brief conversation would be useful. Happy to share more details here as well.

Best regards,
Sangyoon Bae",Associate Director Clinical Operations,Netherlands
Masaaki Usui,JCR Pharmaceuticals,http://www.linkedin.com/in/masaaki-usui-53345a16b,EN,"Hi Usui-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for pharma licensing evaluation.

With JCR expanding its global licensing activity — the Acumen partnership being a recent example — I thought our In-Licensing Workflow AI might be relevant to the global business operations side. It automates key steps in candidate screening, document extraction, and Decision Pack generation, designed to help reduce evaluation turnaround time. Everything runs on-premise with full audit trail. A number of Korean pharmaceutical companies use the tool for similar global licensing evaluations.

I'll be in Tokyo February 16–17 if a short conversation would be useful. Also happy to share more over message.

Best regards,
Sangyoon Bae","Corporate Strategy, Global Business Operations",Japan
Ryo Wakita,JCR Pharmaceuticals,http://www.linkedin.com/in/ryo-wakita-774030304,EN,"Hi Wakita-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for pharma licensing workflows.

With JCR's growing licensed-in portfolio, I thought our In-Licensing Workflow AI might be useful for clinical trial management teams. When new licensed-in assets come in, evaluation prep work — pulling data, organizing documents, building reports — often lands on top of existing trial responsibilities.

Our tool automates document extraction and evaluation report generation, designed to help reduce that added workload. It runs on-premise with full audit trail. We also work with Korean pharma clinical teams on comparable evaluation processes.

I'll be in Tokyo February 16–17 if a short conversation would be helpful. Happy to share details here too.

Best regards,
Sangyoon Bae",Senior Clinical Trial Manager | Clinical Operations,Japan
Anne Bechet,JCR Pharmaceuticals,http://www.linkedin.com/in/anne-bechet-52b8636,EN,"Hi Bechet-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for pharma licensing evaluation.

With JCR's clinical portfolio growing — the recent Acumen Alzheimer's partnership being one example — I thought our In-Licensing Workflow AI might be relevant to your team. As more candidates come in across therapeutic areas, the manual screening work tends to scale faster than the team can.

Our tool automates candidate screening, document extraction, and Decision Pack generation. It deploys on-premise with audit trail and governance compliance. We also support several Korean pharma teams with similar screening workflows.

I'll be in Tokyo February 16–17 if a brief chat would be worthwhile. Also happy to share more details here.

Best regards,
Sangyoon Bae",Global Head of Clinical Development,
Karina Andrade,JCR Pharmaceuticals,http://www.linkedin.com/in/karinadeandrade,EN,"Hi Andrade-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for pharma licensing workflows.

With JCR expanding its global licensing reach, I thought our In-Licensing Workflow AI might be useful for regional BD teams evaluating cross-border opportunities. Each market comes with its own regulatory and data context, and assembling evaluation materials across geographies can be time-consuming.

Our tool automates document extraction, candidate evaluation, and Decision Pack generation — designed to help reduce that manual effort. It runs on-premise with full audit trail. A number of Korean pharmaceutical companies use similar workflows with us.

I'll be in Tokyo February 16–17 if a brief conversation would be helpful. Happy to share more here as well.

Best regards,
Sangyoon Bae",Regional Market & Business Development Director,
Michael Orsini,Eisai,http://www.linkedin.com/in/michael-orsini-01588a1,EN,"Hi Orsini-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise EEG-based AI tools for CNS drug development.

With LEQEMBI SC now approved, I thought our Neuro-Biomarker Co-Scientist might be relevant to your clinical development work. Responder identification in AD trials still relies heavily on cognitive scales that take months to show separation. Our platform uses EEG-AI to predict drug responder status and generates automated research briefs — designed to provide earlier, objective biomarker data.

It deploys fully on-premise with no data leaving your environment. We work with Korean pharma companies on comparable CNS biomarker programs.

I'll be in Tokyo February 16–17 if a brief conversation would be useful.

Best regards,
Sangyoon Bae","Director, Clinical Development Project Management",
Ali Ardati,Eisai,http://www.linkedin.com/in/aliardati,EN,"Hi Ardati-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise EEG-AI tools for CNS drug development.

With evenamide in Phase 3 in Japan, Eisai's CNS pipeline continues to grow — and with it, the need for objective biomarker evidence to complement subjective scales. Traditional cognitive endpoints take time to mature, which can slow development decisions.

Our Neuro-Biomarker Co-Scientist uses EEG-based AI to predict drug responder status and auto-generates research briefs — designed to provide quantifiable data earlier in the process. Everything runs on-premise with no external data transfer. Several Korean pharmaceutical companies are using similar responder stratification workflows with us.

I'll be in Tokyo February 16–17 if a short conversation would be of interest.

Best regards,
Sangyoon Bae","Director, Clinical Project Management",
Pooja Gaikwad,Eisai,http://www.linkedin.com/in/poojagaikwad,EN,"Hi Gaikwad-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for CNS drug development.

With Eisai scaling LEQEMBI across multiple markets, I thought our Neuro-Biomarker Co-Scientist might be worth a look from an R&D IT perspective. It's an EEG-AI platform for drug responder prediction — fully on-premise, no cloud dependency, no external data transfer. The architecture is designed to fit within existing IT governance frameworks rather than requiring exceptions.

It also auto-generates standardized research briefs for internal stakeholders. We support several Korean pharma R&D teams with the same on-premise deployment model.

I'll be in Tokyo February 16–17 if a brief technical conversation would be useful.

Best regards,
Sangyoon Bae","Project and Portfolio Lead, Global R&D IT",
June Nguyen,Eisai,http://www.linkedin.com/in/june-nguyen-a1241b1,EN,"Hi Nguyen-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise EEG-AI tools for CNS drug development.

With Eisai's BioArctic partnership on lecanemab and the broader neuroscience commitment, I thought our Neuro-Biomarker Co-Scientist might be relevant from a business development perspective. Objective biomarker data can strengthen both internal development decisions and external partnership narratives.

Our platform predicts drug responder status using EEG-AI and generates automated research briefs — providing quantifiable data earlier than traditional cognitive endpoints. Everything deploys on-premise, so data stays within your environment. A number of Korean pharma BD teams rely on similar biomarker workflows with us.

I'll be in Tokyo February 16–17 if a brief conversation would be of interest.

Best regards,
Sangyoon Bae","VP Business Development and Head, Established Products",
John Petrera,Eisai,http://www.linkedin.com/in/johnpetrera,EN,"Hi Petrera-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise EEG-AI tools for CNS clinical development.

With LEQEMBI's AD program scaling globally, I thought our Neuro-Biomarker Co-Scientist might be relevant for clinical project management. Responder identification currently relies on cognitive scales that take months to show separation, and ARIA monitoring adds further complexity.

Our platform uses EEG-AI to predict responder status and generates standardized research briefs — designed to provide earlier objective data. Fully on-premise, no data exposure. We also work with Korean pharma teams on similar CNS trial support workflows.

I'll be in Tokyo February 16–17 if a brief conversation would be useful.

Best regards,
Sangyoon Bae","Executive Director, Clinical Project Management",
Mary Ellen,Eisai,http://www.linkedin.com/in/mary-ellen-o-89047210,EN,"Hi Mary Ellen-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise EEG-AI tools for CNS drug development.

With LEQEMBI post-marketing evidence continuing to grow, I thought our Neuro-Biomarker Co-Scientist might be relevant for medical affairs workflows. Turning biomarker data into review-ready summaries can take up a meaningful share of the review cycle.

Our platform auto-generates standardized research briefs from EEG-AI analysis using a consistent pipeline across studies. It runs fully on-premise, so data stays within Eisai's environment. Several Korean pharma medical affairs teams use similar automated briefing workflows with us.

I'll be in Tokyo February 16–17 if a short conversation would be of interest.

Best regards,
Sangyoon Bae","Project Manager, Medical Affairs Strategic Planning and Operations",
Hassan Naqvi,Eisai,http://www.linkedin.com/in/hassan-naqvi,EN,"Hi Naqvi-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for CNS drug development.

As Eisai scales its CNS pipeline across geographies, I thought our Neuro-Biomarker Co-Scientist might be worth a look from a systems perspective. It's an EEG-AI platform for drug responder prediction — fully on-premise, no cloud dependency, no external data transfer. The architecture is designed to integrate within existing infrastructure rather than requiring new data governance exceptions.

It also auto-generates standardized research briefs for internal stakeholders. Korean pharma companies have deployed similar on-premise configurations with us.

I'll be in Tokyo February 16–17 if a brief technical conversation would be useful.

Best regards,
Sangyoon Bae",Sr. Systems Analyst/Project Managment,
Shamara Karunaratne,Eisai,http://www.linkedin.com/in/shamarakarunaratne,EN,"Hi Karunaratne-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for CNS drug development.

With Eisai's CNS-focused strategy, I thought our Neuro-Biomarker Co-Scientist might be relevant from a change management perspective. New analytical platforms in pharma can be difficult to roll out when outputs aren't standardized or easy to interpret.

Our tool uses EEG-AI for responder prediction, runs a standardized pipeline, and auto-generates plain-language research briefs. It deploys on-premise, so no new data governance requirements are introduced. Designed for practical adoption without a steep onboarding curve. We've seen smooth rollouts with Korean pharma teams using this same approach.

I'll be in Tokyo February 16–17 if a brief conversation would be helpful.

Best regards,
Sangyoon Bae","Project Manager, Change Management",
Andrew Pachuta,Eisai,http://www.linkedin.com/in/andrew-pachuta,EN,"Hi Pachuta-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise EEG-AI tools for CNS clinical development.

With LEQEMBI SC approved and ARIA monitoring adding complexity to AD project management, I thought our Neuro-Biomarker Co-Scientist might be relevant. Responder identification currently relies on cognitive scales that take months to mature, which directly affects project timelines.

Our platform uses EEG-AI to predict responder status and generates automated research briefs — designed to provide earlier objective data. It deploys fully on-premise with no data exposure. Several Korean pharma companies use similar EEG-AI workflows for their CNS programs.

I'll be in Tokyo February 16–17 if a brief conversation would be useful.

Best regards,
Sangyoon Bae","Associate Director, Project Management, Alzheimer's Disease",
Helena Heanue-Travers,Eisai Co. Ltd.,http://www.linkedin.com/in/helena-heanue-travers-5540241a,EN,"Hi Helena-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build on-premise AI tools for CNS drug development.

With Eisai expanding LEQEMBI across multiple markets, I thought our Neuro-Biomarker Co-Scientist might be relevant to your clinical operations work. It uses EEG-based AI designed for early responder stratification and auto-generates standardized research briefs -- all on-premise with no external data transfer. We also support Korean pharma clinical operations teams with comparable workflows.

I will be in Tokyo Feb 16-17. If it makes sense, I would welcome a brief conversation about whether this could be useful for Eisai's CNS programs.

Best regards,
Sangyoon Bae",Associate Director of Clinical Operations,Japan
Gregory Seminack,Eisai Co. Ltd.,http://www.linkedin.com/in/gregory-seminack-9760235,EN,"Hi Gregory-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We develop on-premise AI tools for CNS drug development.

With Eisai investing in evenamide Phase 3, I thought our Neuro-Biomarker Co-Scientist might be relevant to R&D finance discussions. It uses EEG-based AI designed for early responder identification, which can support earlier go/no-go decisions and help reduce late-stage trial risk. Fully on-premise, no vendor data access. Korean pharma R&D teams are using similar approaches to support their investment decisions.

I will be in Tokyo Feb 16-17. Would a brief conversation make sense?

Best regards,
Sangyoon Bae","Associate Director, R&D Finance-Preclinical",Japan
Nandan Shah,Eisai Co. Ltd.,http://www.linkedin.com/in/nandan-shah-4727ab3,EN,"Hi Nandan-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for CNS drug development.

Given your role in R&D IT at Eisai, I thought our Neuro-Biomarker Co-Scientist might be worth a quick look. It is an EEG-based AI platform for responder stratification that deploys fully on-premise -- no cloud, no external data transfer. Designed to meet the data governance requirements of global pharma R&D. We work with several Korean pharma IT teams on similar on-premise deployments.

I will be in Tokyo Feb 16-17. Happy to walk through the architecture if helpful.

Best regards,
Sangyoon Bae",Global Head R&D IT,Japan
Daisuke Ito,Eisai Co. Ltd.,http://www.linkedin.com/in/daisuke-ito-07135a25,JA,"伊藤様

この度は繋がりをいただき、誠にありがとうございます。リソリウスのペ・サンユンと申します。

※もしご関心がございませんでしたら、ご放念くださいませ。

エーザイ様はCNS領域に注力され、AD治療薬をはじめとする重要な開発を推進されていると存じます。

弊社のNeuro-Biomarker Co-Scientistは、脳波（EEG）ベースのAIでレスポンダーの早期特定を支援し、客観的バイオマーカーによる治療効果の客観的な評価を支援します。オンプレミス導入のためデータ漏洩の懸念もございません。韓国の複数の製薬企業様にも同様のソリューションをご導入いただいております。

2月16〜17日に東京におりますので、30分ほどお時間をいただけますでしょうか。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomでも対応可能です。

何卒よろしくお願い申し上げます。

ペ・サンユン
創業者
リソリウス","Director, Corporate Business Development",Japan
Yoshitaka Maeda,Eisai Co. Ltd.,http://www.linkedin.com/in/yoshitaka-maeda-6b16a923a,EN,"Hi Yoshitaka-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we develop on-premise AI tools for CNS drug development.

With Eisai's LEQEMBI partnerships continuing to expand globally, I thought our Neuro-Biomarker Co-Scientist might be relevant. It provides EEG-based responder stratification with auto-generated research briefs -- the kind of objective biomarker data that can strengthen both internal evaluation and partnership discussions. A number of Korean pharmaceutical companies leverage similar biomarker evidence with us.

I will be in Tokyo Feb 16-17 and would welcome a brief conversation if this seems useful.

Best regards,
Sangyoon Bae",Director of Business Development,Japan
Osamu Kikuchi,Eisai Co. Ltd.,http://www.linkedin.com/in/osamu-kikuchi-48816524,EN,"Hi Osamu-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for CNS drug development.

As Eisai's CNS programs expand, I thought our Neuro-Biomarker Co-Scientist might be relevant to R&D team development. It provides EEG-based responder stratification with a standardized pipeline and auto-generated research briefs -- designed to make biomarker insights accessible to broader team members without specialist training. Korean pharma R&D teams have adopted the same platform for their training and onboarding needs.

I will be in Tokyo Feb 16-17. Happy to share more if useful.

Best regards,
Sangyoon Bae",Head of DHBL (Global R&D) Human Resource Strategy & Operations,Japan
Kentaro Nagane,Eisai Co. Ltd.,http://www.linkedin.com/in/kentaro-nagane-ab044b126,EN,"Hi Kentaro-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we develop on-premise AI tools for CNS drug development.

With Eisai's corporate strategy deeply focused on CNS, I thought our Neuro-Biomarker Co-Scientist might be worth exploring. It is an EEG-based AI platform designed for responder stratification, with a standardized pipeline and auto-generated briefs -- the kind of biomarker infrastructure that could support long-term portfolio planning. We work with Korean pharma companies on comparable strategic biomarker initiatives.

I will be in Tokyo Feb 16-17. Would a brief conversation be useful?

Best regards,
Sangyoon Bae","Associate Director, Corporate Planning",Japan
Jason Lo,Eisai Co. Ltd.,http://www.linkedin.com/in/jason-lo-b4828838,EN,"Hi Jason-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for CNS drug development.

With LEQEMBI subcutaneous now approved and AD market competition growing, I thought our Neuro-Biomarker Co-Scientist might be relevant. It uses EEG-based AI for responder stratification, producing objective biomarker data that can support both regulatory filings and commercial positioning. Fully on-premise. Several Korean pharma companies use similar biomarker data to strengthen their commercial narratives.

I will be in Tokyo Feb 16-17. Would a brief conversation make sense?

Best regards,
Sangyoon Bae",Head of Marketing & Business Development,Japan
Hiroyuki Muramatsu,Eisai Co. Ltd.,http://www.linkedin.com/in/hiroyuki-muramatsu-536627b6,JA,"村松様

この度は繋がりをいただき、誠にありがとうございます。リソリウスのペ・サンユンと申します。

※もしご関心がございませんでしたら、ご放念くださいませ。

東アジア・グローバルサウスにおけるエーザイ様のCNS事業は、LEQEMBI皮下注の承認をはじめ大きな転換期を迎えていると存じます。

弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIでレスポンダーの早期特定を支援するプラットフォームです。客観的バイオマーカーによる治療効果の客観的な評価が可能で、オンプレミス導入のためデータ漏洩リスクもございません。韓国の複数の製薬企業様とも同様の取り組みで協業を進めております。

2月16〜17日に東京におります。30分ほどお時間をいただき、東アジア地域でのCNS開発への活用についてご相談できればと存じます。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

ペ・サンユン
創業者
リソリウス","Sr. Director, Regional BD Head, East Asia and Global South Region",Japan
Sara Pena Martinez,Eisai Co. Ltd.,http://www.linkedin.com/in/sara-pe%c3%b1a-mart%c3%adnez-0632a297,EN,"Hi Sara-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we develop on-premise AI tools for CNS drug development.

Marketing CNS therapies around subjective endpoints is a well-known challenge. Our Neuro-Biomarker Co-Scientist uses EEG-based AI for responder stratification, generating objective biomarker data that can complement your marketing narratives for Eisai's AD portfolio. We also support Korean pharma marketing teams with similar objective evidence workflows.

I will be in Tokyo Feb 16-17 and would welcome a brief conversation if this seems relevant to your work.

Best regards,
Sangyoon Bae",Marketing Manager - Central Nervous System (CNS) Therapies,Japan
Yoshimi Kuroiwa,Otsuka Pharmaceutical Co. Ltd.,http://www.linkedin.com/in/yoshimi-kuroiwa-ph-d-547986183,JA,"黒岩様

つながりをいただきありがとうございます。リソリウスの創業者のペ・サンユンと申します。

※ご関心がなければご放念くださいませ。

大塚製薬様は精神・神経領域がパイプラインの最重点カテゴリーであり、centanafadineのPDUFA 2026年7月やbrexpiprazole週1回経口剤の国内Phase 3など、重要な開発が進行中と存じます。

弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIでレスポンダーの早期特定を支援し、客観的バイオマーカーで治療効果の客観的な評価を支援します。標準化された解析パイプラインと自動生成レポートにより、解析業務の効率化に寄与します。オンプレミス導入でデータ漏洩の懸念もございません。現在、韓国の製薬企業数社にも同様のプラットフォームをご利用いただいております。

2月16〜17日に東京におります。30分ほどお時間をいただけますでしょうか。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

ペ・サンユン","Senior Director, Pharmaceutical Business Division",Japan
Masahiro Kajita,Otsuka Pharmaceutical Co. Ltd.,http://www.linkedin.com/in/masahiro-kajita-879627118,JA,"梶田様

つながりをいただきありがとうございます。リソリウスの創業者のペ・サンユンと申します。

※ご関心がなければご放念くださいませ。

大塚製薬様はulotarontの完全自社化をはじめ、精神・神経領域のパイプラインを積極的に拡充されていると存じます。

弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIでレスポンダーの早期特定を支援し、治療効果を客観的バイオマーカーで評価するプラットフォームです。オンプレミス導入でデータ漏洩の懸念もございません。韓国の製薬企業数社にも同様の業務支援でご導入いただいております。

2月16〜17日に東京におりますので、30分ほどお時間をいただけますでしょうか。対面が難しい場合はZoomでも対応可能です。

何卒よろしくお願い申し上げます。

ペ・サンユン",Business Development Manager,Japan
Janelle Burnham,Otsuka Pharmaceutical Co. Ltd.,http://www.linkedin.com/in/janelleburnham,EN,"Hi Janelle-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we develop on-premise AI tools for CNS drug development.

With Otsuka's psychiatry and neurology pipeline being a key focus area, I thought our Neuro-Biomarker Co-Scientist might be relevant. It provides EEG-based responder stratification, offering an objective biomarker layer alongside traditional clinical scales. Standardized pipeline, auto-generated briefs, fully on-premise. Korean pharma companies run similar CNS biomarker workflows with us.

I will be in Tokyo Feb 16-17. Would a brief conversation be helpful?

Best regards,
Sangyoon Bae",Global Clinical Development Lead,Japan
Hitomi Kawaguchi,Otsuka Pharmaceutical Co. Ltd.,http://www.linkedin.com/in/hitomi-kawaguchi-a9071b72,JA,"川口様

つながりをいただきありがとうございます。リソリウスの創業者のペ・サンユンと申します。

※ご関心がなければご放念くださいませ。

大塚製薬様では精神・神経領域がパイプラインの最重点カテゴリーであり、centanafadine（PDUFA 2026年7月）やbrexpiprazole週1回経口剤のPhase 3など、臨床開発計画の重要局面にあると存じます。

精神科領域の課題は、主観的評価尺度に依存した応答者特定の難しさです。弊社のNeuro-Biomarker Co-Scientistは脳波ベースのAIでレスポンダーの早期特定を支援し、客観的バイオマーカーによる治療効果の客観的な評価を支援します。オンプレミスで導入でき、自動レポート生成機能も備えています。韓国の製薬企業数社と同様の課題解決で協業実績がございます。

2月16〜17日に東京におります。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

ペ・サンユン",Data analyst / Clinical development,Japan
Mohit Patel,Otsuka Pharmaceutical Co. Ltd.,http://www.linkedin.com/in/mohit-patel-097268157,EN,"Hi Mohit-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we develop on-premise AI tools for CNS drug development.

With Otsuka's psychiatry and neurology pipeline being the company's leading category, I thought our Neuro-Biomarker Co-Scientist might be relevant to your BD work. It provides EEG-based responder stratification with auto-generated research briefs -- objective biomarker evidence that can support asset evaluation and positioning. We also work with Korean pharma BD teams on comparable evaluation processes.

I will be in Tokyo Feb 16-17. Would a brief conversation be useful?

Best regards,
Sangyoon Bae",,
Kazuto Yamada,Otsuka Pharmaceutical Co. Ltd.,http://www.linkedin.com/in/kazuto-yamada-1a24953b,JA,"山田様

つながりをいただきありがとうございます。リソリウスの創業者のペ・サンユンと申します。

※ご関心がなければご放念くださいませ。

大塚製薬様にて臨床開発計画の統括および5つのR&D機能を監督されている山田様に、精神・神経領域の開発を加速する新たなアプローチをご提案いたします。

centanafadine（PDUFA 2026年7月）、brexpiprazole週1回経口剤Phase 3、REXULTI depot Phase Iと、複数の重要プログラムが同時進行する中、客観的バイオマーカーによる応答者特定が開発効率を左右します。

弊社のNeuro-Biomarker Co-Scientistは脳波ベースのAIでレスポンダーの早期特定を支援します。標準化解析パイプラインと自動レポート生成機能を備え、オンプレミスで導入可能です。韓国の製薬企業数社にも同様の評価支援業務でご利用いただいております。

2月16〜17日に東京にてお打ち合わせのお時間をいただけますでしょうか。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

ペ・サンユン","Director, Head of Clinical Development Planning and Supervising five R&D Function",Japan
Iku Nakayama,Otsuka Pharmaceutical Co. Ltd.,http://www.linkedin.com/in/iku-nakayama-75a30398,JA,"中山様

つながりをいただきありがとうございます。リソリウスの創業者のペ・サンユンと申します。

※ご関心がなければご放念くださいませ。

大塚製薬様のデジタルビジネス推進室では、精神・神経領域をはじめとするパイプラインのデジタル化推進において、データセキュリティとQMS要件の両立が重要課題かと存じます。

弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIでレスポンダーの早期特定を支援するプラットフォームです。完全オンプレミス導入のためデータ漏洩リスクがなく、標準化された解析パイプラインはQMS要件との整合性も取りやすい設計です。韓国の製薬企業数社にも同様のワークフロー効率化でご活用いただいている実績がございます。

2月16〜17日に東京におります。ご都合のよいお時間帯をお知らせいただけますと幸いです。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

ペ・サンユン","Manager, Digital Business Office and Pharmaceutical Business QMS",Japan
Yoshitaka Kotobuki,Otsuka Pharmaceutical Co. Ltd.,http://www.linkedin.com/in/yoshitaka-kotobuki-1480b879,JA,"寿様

つながりをいただきありがとうございます。リソリウスの創業者のペ・サンユンと申します。

※ご関心がなければご放念くださいませ。

大塚製薬様のSmall Global R&D部門では、限られたリソースでcentanafadine（PDUFA 2026年7月）やbrexpiprazole週1回経口剤Phase 3など、精神・神経領域の重要な開発を推進されていると存じます。

少人数チームでは、バイオマーカー解析から社内レビュー資料作成まで手作業が多くなりがちです。弊社のNeuro-Biomarker Co-Scientistは脳波ベースAIでレスポンダーの早期特定を支援し、標準化パイプラインと自動レポート生成で解析業務の効率化に寄与します。オンプレミス導入でデータ管理も安心です。韓国の製薬企業数社とも同様の解析効率化で協業しております。

2月16〜17日に東京におります。30分ほどお打ち合わせのお時間をいただけますでしょうか。対面が難しい場合はZoomも可能です。

何卒よろしくお願い申し上げます。

ペ・サンユン",Head of small Global R&D Department,Japan
Bernadette Donohue,Otsuka Pharmaceutical,http://www.linkedin.com/in/bernadette-donohue-9764811,EN,"Hi Bernadette-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for CNS drug development.

With centanafadine heading toward PDUFA in July 2026, I thought our Neuro-Biomarker Co-Scientist might be relevant to your sourcing work. It is an EEG-based AI platform for responder stratification -- designed to support CNS trial decisions with auto-generated research briefs. Fully on-premise, no vendor data access. Several Korean pharma procurement teams have sourced similar platforms from us.

I will be in Tokyo Feb 16-17. Would a brief conversation be useful?

Best regards,
Sangyoon Bae",,United States
Michael Krause,Otsuka Pharmaceutical,http://www.linkedin.com/in/gmichaelkrause,EN,"Hi Michael-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we develop on-premise AI tools for CNS drug development.

With centanafadine heading toward PDUFA, I thought our Neuro-Biomarker Co-Scientist might be relevant to your CNS project management. It uses EEG-based AI designed for early responder identification, with auto-generated research briefs for project reviews. Fully on-premise. We support Korean pharma project teams with similar CNS development workflows.

I will be in Tokyo Feb 16-17. Happy to walk through the platform if helpful.

Best regards,
Sangyoon Bae",,United States
Philomene Akafack,Otsuka Pharmaceutical,http://www.linkedin.com/in/philomene-akafack-pmp-a14ba8b2,EN,"Hi Philomene-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for CNS drug development.

With psychiatry and neurology as Otsuka's leading pipeline category, I thought our Neuro-Biomarker Co-Scientist might be relevant. It uses EEG-based AI designed for early responder stratification -- providing an objective complement to traditional psychiatric scales. Auto-generated research briefs and fully on-premise. A number of Korean pharma teams use similar stratification approaches with us.

I will be in Tokyo Feb 16-17. Would a brief conversation make sense?

Best regards,
Sangyoon Bae",,
Thomas Thompson,Otsuka Pharmaceutical,http://www.linkedin.com/in/thomas-thompson-796b6615,EN,"Hi Thomas-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for CNS drug development.

With centanafadine heading toward PDUFA and Otsuka's broad CNS portfolio, I thought our Neuro-Biomarker Co-Scientist might be worth exploring. It uses EEG-based AI designed for responder stratification, with a standardized pipeline and auto-generated briefs. We work with Korean pharma companies exploring similar biomarker integration across their portfolios. Your perspective on where objective biomarkers could fit across Otsuka's programs would be very helpful.

I will be in Tokyo Feb 16-17. Would a brief conversation make sense?

Best regards,
Sangyoon Bae",,
Saki Sakurai (櫻井),Sumitomo Pharma Co. Ltd.,http://www.linkedin.com/in/saki-sakurai-8688201ba,JA,"櫻井様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。

住友ファーマ様がCNS営業部を独立組織として維持され、CNS領域の臨床研究インフラを大切にされていると伺いました。

臨床研究において、薬剤応答者の早期特定は試験効率を左右する重要課題かと存じます。弊社のNeuro-Biomarker Co-Scientistは脳波ベースのAIでレスポンダーの早期特定を支援し、標準化された解析パイプラインと自動レポート生成機能を備えております。オンプレミス導入でデータ管理も安心です。韓国の製薬企業数社にも同様のプラットフォームをご活用いただいております。

2月16〜17日に東京におりますので、お時間をいただけるようでしたらお打ち合わせの機会を頂ければ幸いです。Zoomでも対応可能です。

ご多忙のところ恐れ入りますが、ご検討いただけますと幸いです。ご不要でしたらご放念くださいませ。

何卒よろしくお願い申し上げます。",Clinical Research,Japan
Shunichiro Uesugi (上杉),Sumitomo Pharma Co. Ltd.,http://www.linkedin.com/in/shunichiro-uesugi-8910aa1a9,JA,"上杉様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。

住友ファーマ様がオンコロジー・再生医療へのピボットを進める一方、CNS営業部を独立組織として維持されていること、CNS領域の商業インフラという貴重な資産をお持ちであると存じます。

このCNS基盤を最大限活用するために、弊社のNeuro-Biomarker Co-Scientistをご紹介できればと思います。脳波ベースのAIで薬剤レスポンダーの早期特定を支援し、標準化された解析パイプラインと自動レポート生成機能を備えたプラットフォームです。オンプレミス導入でデータ管理も安心です。韓国の製薬企業数社にも同様のAI活用で協業を進めております。

2月16〜17日に東京におりますので、お打ち合わせの機会を頂ければ幸いです。Zoomでも対応可能です。

ご不要でしたらどうぞご放念くださいませ。

何卒よろしくお願い申し上げます。",Sumitomo Pharma - R&D Strategy and Planning,Japan
Shogo Shibata (柴田),Sumitomo Pharma Co. Ltd.,http://www.linkedin.com/in/shogo-shibata-12b946319,JA,"柴田様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。

住友ファーマ様がCNS営業部を独立組織として維持される中、柴田様がCNS製品マーケティングのシニアディレクターとしてこの領域の商業価値を守り発展させていらっしゃると存じます。

CNS製品のマーケティングでは、主観的評価尺度に基づくエビデンスだけでは差別化が困難な場面もあるかと思います。弊社のNeuro-Biomarker Co-Scientistは脳波ベースのAIでレスポンダーの早期特定を支援し、客観的バイオマーカーによる治療効果の客観的な評価を支援します。オンプレミス導入でデータ管理も万全です。韓国の製薬企業数社にも同様の自動化ソリューションでご活用いただいております。

2月16〜17日に東京におります。お打ち合わせのお時間をいただけますでしょうか。Zoomも可能です。

ご不要でしたらどうぞご放念くださいませ。

何卒よろしくお願い申し上げます。",Sumitomo Pharma CNS Product Marketing,Japan
Tomoko Goda (合田),Sumitomo Pharma Co. Ltd.,http://www.linkedin.com/in/tomoko-goda-69939020,JA,"合田様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。

住友ファーマ様がulotarontの大塚製薬への移管後もCNS営業部を独立維持されており、今後の提携戦略において差別化できる技術基盤が重要になると存じます。

弊社のNeuro-Biomarker Co-Scientistは、脳波ベースのAIでレスポンダーの早期特定を支援するプラットフォームです。客観的バイオマーカーによる治療効果の評価、標準化パイプライン、自動レポート生成機能を備え、オンプレミス導入でデータ管理も安心です。韓国の複数の製薬企業様にも同様のレスポンダー予測業務でご利用いただいております。

2月16〜17日に東京におりますので、お打ち合わせの機会を頂ければ幸いです。Zoomでも対応可能です。

ご不要でしたらどうぞご放念くださいませ。

何卒よろしくお願い申し上げます。","Business Development, Alliance Marketing",Japan
Cristian Nita,Sumitomo Pharma,http://www.linkedin.com/in/cristian-nita-b2b640272,EN,"Hi Cristian-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for CNS drug development.

With Sumitomo Pharma's portfolio evolving, I thought our Neuro-Biomarker Co-Scientist might be worth exploring for any current or future CNS work. It uses EEG-based AI designed for responder stratification, with a standardized pipeline and auto-generated research briefs. Fully on-premise. Several Korean pharmaceutical companies use similar platforms for their CNS programs.

I will be in Tokyo Feb 16-17. Would a brief conversation make sense?

Best regards,
Sangyoon Bae",,
Christina Kelly,Takeda,http://www.linkedin.com/in/christina-tascione-kelly-71430358,EN,"Hi Christina-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for CNS drug development.

With TAK-861 advancing in narcolepsy, I thought our Neuro-Biomarker Co-Scientist might be relevant to your work. It uses EEG-based AI designed for responder stratification and auto-generates standardized research briefs, all running within your own infrastructure. Korean pharma companies use similar EEG-AI platforms for their own CNS trials.

Would you be open to a brief conversation? I'll be in Tokyo February 16-17, and Zoom works too.

Best regards,
Sangyoon Bae",,
Shashank Shanbhag,Takeda,http://www.linkedin.com/in/shashank-shanbhag-3709561,EN,"Hi Shashank-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we develop on-premise AI tools for CNS drug programs.

As Takeda prepares to commercialize its orexin-based portfolio, I thought our Neuro-Biomarker Co-Scientist might be useful. It provides EEG-based objective biomarker data designed to support responder stratification and value dossier development. We also work with Korean pharma commercial teams on similar biomarker-driven positioning.

Would you be open to a short conversation? I'll be in Tokyo February 16-17, and Zoom is fine too.

Best regards,
Sangyoon Bae",,
Charlotte Barry-Delongchamps,Takeda,http://www.linkedin.com/in/charlotte-barry-delongchamps-2988725,EN,"Hi Charlotte-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI platforms for CNS drug development.

Given Takeda's growing focus on AI-driven innovation, I thought our Neuro-Biomarker Co-Scientist might be relevant to your emerging market BD work. It uses EEG-based AI for responder stratification and runs fully on-premise, making it deployable across varied regulatory environments. Several Korean pharma companies deploy similar on-premise setups across their regional operations.

Would you be open to a short conversation? I'll be in Tokyo February 16-17, and Zoom works too.

Best regards,
Sangyoon Bae",,
Antonio Toma,Takeda,http://www.linkedin.com/in/antonio-raffaele-toma-2613244,EN,"Hi Antonio-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we develop on-premise AI platforms for CNS drug development.

As Takeda expands AI partnerships, data governance in cross-border deals becomes critical. Our Neuro-Biomarker Co-Scientist runs fully on-premise with no data leaving your systems, designed to simplify compliance while providing objective CNS biomarker analysis. We also support several Korean pharma companies with similar on-premise deployment workflows.

Would you be open to a brief conversation? I'll be in Tokyo February 16-17, and Zoom works too.

Best regards,
Sangyoon Bae",,
Francis Fordjour,Takeda,http://www.linkedin.com/in/francis-fordjour-ph-d-4231b115b,EN,"Hi Francis-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for CNS drug development.

With TAK-861 advancing in narcolepsy, I thought our Neuro-Biomarker Co-Scientist might be relevant to portfolio-level decision-making. It uses EEG-based AI designed for responder stratification, helping generate objective signals earlier in the pipeline. A number of Korean pharmaceutical companies use similar workflows with us.

Would you be open to a brief conversation? I'll be in Tokyo February 16-17, and Zoom works too.

Best regards,
Sangyoon Bae",I’m a strategic leader in the biopharmaceutical industry with deep expertise in R&D…,United States
Ronan Fitzgerald,Takeda,http://www.linkedin.com/in/ronan-fitzgerald-727a7914,EN,"Hi Ronan-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we develop on-premise AI platforms for CNS drug development.

Given Takeda's growing interest in AI-driven partnerships, I thought our Neuro-Biomarker Co-Scientist might be worth a brief look. It uses EEG-based AI for responder stratification and runs fully on-premise, designed for translational neuroscience research. We work with Korean pharma companies on comparable evaluation processes.

Would you be open to a short conversation? I'll be in Tokyo February 16-17, and Zoom works too.

Best regards,
Sangyoon Bae",,
Takahiro Imanaka,Takeda,http://www.linkedin.com/in/takahiro-imanaka-phd-7331a31a0,EN,"Hi Takahiro-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for CNS drug development.

With TAK-861 advancing and Japan's data residency requirements in mind, I thought our Neuro-Biomarker Co-Scientist might be relevant. It runs fully on-premise and uses EEG-based AI for responder stratification, with auto-generated briefs to help streamline PMDA documentation. Several Korean pharma teams already rely on similar workflows with us.

Would you be open to a brief conversation? I'll be in Tokyo February 16-17.

Best regards,
Sangyoon Bae",Head of Japan Development | Clinical Development Expert | Successful Global Project Management | Regulatory Affairs Leader | Cross-Functional Leadership | Leader in Medical Research | Vaccine | Ophthalmology,Japan
Chris Hurff,Takeda,http://www.linkedin.com/in/chris-hurff-a4803585,EN,"Hi Chris-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we develop on-premise AI platforms for CNS research.

With Takeda's work in orexin biology and TAK-861 advancing, I thought our Neuro-Biomarker Co-Scientist might be worth a look. It provides EEG-based responder stratification and auto-generated research briefs, designed to support CNS research collaborations. We also work with several Korean pharma companies on similar research support workflows.

Would you be open to a brief conversation? I'll be in Tokyo February 16-17, and Zoom is fine too.

Best regards,
Sangyoon Bae",,United States
Zachary Cary,Takeda,http://www.linkedin.com/in/zachary-cary-5643931,EN,"Hi Zachary-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for CNS drug development.

Given Takeda's commitment to AI-driven innovation, I thought our Neuro-Biomarker Co-Scientist might be worth discussing. It uses EEG-based AI for responder stratification and objective biomarker quantification, running fully within your own infrastructure. In fact, Korean pharmaceutical companies are using comparable pipelines with us as well.

Would you be open to a brief conversation? I'll be in Tokyo February 16-17, and Zoom works too.

Best regards,
Sangyoon Bae",,United States
Gina Cerrato,Takeda,http://www.linkedin.com/in/gina-cerrato-88a9a32b5,EN,"Hi Gina-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we develop on-premise AI tools for CNS drug programs.

With TAK-861 advancing toward regulatory submissions, I thought our Neuro-Biomarker Co-Scientist might be relevant to your R&D operations. It provides a standardized EEG analysis pipeline with auto-generated research briefs, designed to help reduce workload across teams. We support several Korean pharma R&D teams with similar analysis workflows.

Would you be open to a brief conversation? I'll be in Tokyo February 16-17, and Zoom works too.

Best regards,
Sangyoon Bae",,
Teresa Yang,Takeda,http://www.linkedin.com/in/teresa-yang-7981195b,EN,"Hi Teresa-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for CNS drug development.

With TAK-861 moving into regulatory submissions, I thought our Neuro-Biomarker Co-Scientist might be useful for your project management work. It provides objective EEG-based biomarker data with auto-generated briefs, designed to help reduce analysis time for project teams. A number of Korean pharma teams use similar setups with us.

Would you be open to a brief conversation? I'll be in Tokyo February 16-17, and Zoom works too.

Best regards,
Sangyoon Bae",,United States
Frank Tamburro,Takeda,http://www.linkedin.com/in/frank-tamburro-b540a91,EN,"Hi Frank-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we develop on-premise AI platforms for CNS clinical operations.

I thought our Neuro-Biomarker Co-Scientist might be relevant as Takeda evaluates AI tools. It runs fully on-premise with no data leaving your systems, provides objective CNS biomarker analysis, and is designed to reduce reliance on external analytics vendors. We also work with Korean pharma companies on similar vendor-consolidation workflows.

Would you be open to a brief conversation? I'll be in Tokyo February 16-17, and Zoom works too.

Best regards,
Sangyoon Bae","R&D Procurement Lead: Clinical Operations Business Partners Team, Post Approval and FSP Categories",
Barbara Mawhinney,Takeda,http://www.linkedin.com/in/barbaramawhinney,EN,"Hi Barbara-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we build on-premise AI tools for CNS drug development.

With TAK-861 advancing and European submissions on the horizon, I thought our Neuro-Biomarker Co-Scientist might be relevant to your R&D operations. It provides EEG-based responder stratification with auto-generated briefs, running fully on-premise to support GDPR-compliant data handling. Several Korean pharmaceutical companies use similar compliance-focused workflows with us.

Would you be open to a brief conversation? I'll be in Tokyo February 16-17, and Zoom works too.

Best regards,
Sangyoon Bae","Strategy & Business Operations Lead, R&D Europe",
Bassem Mattar,Takeda,http://www.linkedin.com/in/bassem-mattar-25877335,EN,"Hi Bassem-san,

Thank you for connecting. I'm Sangyoon Bae, Founder at RISORIUS — we develop on-premise AI platforms for CNS drug programs.

As Takeda expands its CNS portfolio into emerging markets, I thought our Neuro-Biomarker Co-Scientist might be worth discussing. It provides EEG-based responder stratification with objective data, running fully on-premise to meet varied data sovereignty requirements. We also support Korean pharma teams with comparable cross-border deployment setups.

Would you be open to a brief conversation? I'll be in Tokyo February 16-17, and Zoom is fine too.

Best regards,
Sangyoon Bae",Head of Business Development & Alliance Management - Emerging Markets,
Michelle McManus,Takeda,http://www.linkedin.com/in/michelle-mcmanus,EN,"Hi Michelle-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS -- we build on-premise AI tools for pharma R&D teams.

With TAK-861 progressing through Phase 3, I thought our Neuro-Biomarker Co-Scientist might be relevant to your work supporting translational talent. It uses EEG-based AI to help predict drug responders and auto-generate research briefs, designed to reduce time spent on manual biomarker analysis. Several Korean pharma companies run similar biomarker analysis workflows with us.

I will be in Tokyo February 16-17. Would you be open to a brief conversation about whether this fits your team's roadmap? Happy to do Zoom as well.

Looking forward to hearing from you.

Best,
Sangyoon Bae","Head, Learning & Talent Development, Global Oncology and U.S. Business Unit",
Leslie Cousens,Takeda,http://www.linkedin.com/in/leslie-cousens-95817755,EN,"Hi Leslie-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We develop on-premise AI tools for pharma, focused on CNS biomarker analysis.

Given your role in Takeda's External Innovation group, I thought our Neuro-Biomarker Co-Scientist might be worth a look. It uses EEG-based AI for drug responder stratification and auto-generates standardized research briefs -- all deployed on-premise with no data leaving your infrastructure. We designed it specifically for teams that need objective biomarker quantification without compromising data governance. A number of Korean pharma companies use the platform for similar evaluation needs.

I will be in Tokyo February 16-17 if a short meeting works, or happy to do Zoom at your convenience. No pressure either way.

Best,
Sangyoon Bae","Senior Director, GI Search & Evaluation Lead, R&D BD Center for External Innovation",
Taisei Masuda,Takeda,http://www.linkedin.com/in/taisei-masuda-0562685,EN,"Hi Taisei-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. Congratulations on TAK-861's Phase 3 results for narcolepsy type 1.

We built the Neuro-Biomarker Co-Scientist -- an EEG-based AI platform designed to predict drug responders and quantify treatment effects through objective biomarkers. It runs fully on-premise with zero data leakage, which may be relevant as you shape Japan CNS regulatory strategy. The standardized pipeline also auto-generates research briefs to help reduce manual analysis steps. We work with several Korean pharma teams on comparable regulatory-support workflows.

I will be in Tokyo February 16-17. Would you be open to a short conversation about potential fit? Zoom also works if that is easier.

Best,
Sangyoon Bae","Director, Japan Project Lead, Therapeutic Area Strategy Unit",Japan
Nancy Mastrangelo,Takeda,http://www.linkedin.com/in/nancy-mastrangelo-ba37b412,EN,"Hi Nancy-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma R&D, with a strong focus on data governance.

Our Neuro-Biomarker Co-Scientist uses EEG-based AI for drug responder prediction and auto-generates standardized research briefs. It deploys entirely on-premise with zero patient data leaving your infrastructure, and includes a built-in audit trail -- which I thought might align well with Patient Safety's vendor evaluation requirements for CNS programs. Korean pharmaceutical companies also use this platform for similar governance-focused deployments.

I will be in Tokyo February 16-17 if a short meeting works, or happy to arrange a Zoom call at your convenience. No pressure either way.

Best,
Sangyoon Bae","Head of Business Development, Alliance Management & Vendor Oversight, Patient Safety",
Eric Yeung,Takeda,http://www.linkedin.com/in/eric-yeung-7b5a755,EN,"Hi Eric-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We develop on-premise EEG-based AI tools for CNS drug development.

For rare neurological diseases, where patient stratification is especially high-stakes, our Neuro-Biomarker Co-Scientist is designed to predict drug responders and quantify treatment effects using objective biomarkers. It auto-generates standardized research briefs and runs fully on-premise, so data governance is built in from the start. We also support several Korean pharma companies with similar stratification workflows.

I will be in Tokyo February 16-17. Would you be open to a brief conversation about potential fit with Takeda's rare disease portfolio? Happy to do Zoom as well if that works better.

Best,
Sangyoon Bae","VP, Head of Oncology and Rare Diseases Global Business Development",
Kae Matsuda,Takeda,http://www.linkedin.com/in/kae-matsuda-4568231aa,EN,"Hi Kae-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. With TAK-861's Phase 3 results and global submissions underway, I thought our work might be timely for Japan R&D planning.

We built the Neuro-Biomarker Co-Scientist -- an EEG-based AI platform designed to predict drug responders and generate standardized research briefs. It quantifies treatment effects using objective EEG biomarkers and deploys fully on-premise, so no data leaves your environment. Could be useful for both regulatory positioning and clinical evidence planning. Several Korean pharma teams rely on similar evidence-generation pipelines with us.

I will be in Tokyo February 16-17. Would a short conversation make sense? Happy to do Zoom as well.

Best,
Sangyoon Bae","Associate Director, Strategy Planning Office, R&D Japan Region",Japan
Ploy Rainville,Takeda,http://www.linkedin.com/in/ploy-rainville-5549017,EN,"Hi Ploy-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma CNS programs.

With TAK-861's Phase 3 results and global submissions underway, I thought our Neuro-Biomarker Co-Scientist might be relevant to business strategy discussions. It uses EEG-based AI to predict drug responders and auto-generate standardized research briefs -- designed to provide objective biomarker data for portfolio decisions. Deploys fully on-premise with zero data leakage. Notably, we work with Korean pharma companies on similar portfolio-level decision support.

I will be in Tokyo February 16-17. Would you be open to a short conversation about potential fit? Zoom works as well if scheduling is easier.

Best,
Sangyoon Bae","Senior Director, Head of Business Strategy Development & Deployment",
Shamira Shariffudin,Takeda,http://www.linkedin.com/in/shamira-shariffudin-56a2ab100,EN,"Hi Shamira-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We develop on-premise EEG-based AI for CNS drug development.

As Takeda's BD team evaluates complementary technologies for the CNS portfolio, I thought our Neuro-Biomarker Co-Scientist might be worth a conversation. It is designed to predict drug responders objectively using EEG biomarkers and auto-generate standardized research briefs. The platform deploys fully on-premise, so data governance is handled from the start. A number of Korean pharmaceutical companies use us for comparable BD evaluation workflows.

I will be in Tokyo February 16-17 -- would a short meeting work? Happy to do Zoom instead if that is easier. No pressure either way.

Best,
Sangyoon Bae",Head of Business Development Strategy,
Jen Rice,Takeda,http://www.linkedin.com/in/jenricephd,EN,"Hi Jen-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise EEG-based AI tools for CNS biomarker analysis.

With growing interest in the gut-brain axis, I thought our Neuro-Biomarker Co-Scientist might be relevant to Takeda's GI programs -- especially for compounds with CNS-adjacent endpoints like cognitive symptoms in IBD. It is designed to predict drug responders, quantify treatment effects with objective biomarkers, and generate standardized research briefs. Fully on-premise with zero data leakage. In fact, several Korean pharma teams use similar biomarker quantification pipelines with us.

I will be in Tokyo February 16-17. Would a short conversation make sense? Zoom works too if scheduling is easier.

Best,
Sangyoon Bae","Head, GI & Inflammation, Global Business Development",
Ceri Davies,Takeda,http://www.linkedin.com/in/ceri-davies-633358ab,EN,"Hi Ceri-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. Congratulations on TAK-861's Phase 3 results -- strong validation of Takeda's orexin biology platform.

We built the Neuro-Biomarker Co-Scientist to help address the gap in objective, translatable biomarkers for early CNS discovery. It uses EEG-based AI for responder prediction, quantifies treatment effects, and auto-generates standardized research briefs. Everything runs on-premise with zero data leakage, so it fits into existing security requirements. We also work with Korean pharma companies on similar early-stage discovery pipelines.

I will be in Tokyo February 16-17. Would a brief conversation about fit with your discovery pipeline make sense? Happy to do Zoom as well.

Best,
Sangyoon Bae",Head of CNS Drug Discovery Unit,Japan
Belinda King,Takeda,http://www.linkedin.com/in/belinda-king,EN,"Hi Belinda-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We develop on-premise AI tools for pharma biomarker analysis.

With TAK-861 heading toward global regulatory submissions, I thought our Neuro-Biomarker Co-Scientist might be relevant to your QA workflows. It provides a standardized EEG analysis pipeline with auto-generated research briefs and a built-in audit trail -- designed for reproducibility and consistency across multiple sites. The platform deploys fully on-premise with zero data leakage, which helps with data integrity requirements. Korean pharma companies also rely on us for similar multi-site QA processes.

I will be in Tokyo February 16-17. Would a short conversation work? Happy to do Zoom instead if scheduling is easier.

Best,
Sangyoon Bae","Research QA Project Lead, Associate Director",
Preety Mishraa,Takeda,http://www.linkedin.com/in/preety-mishraa-187767109,EN,"Hi Preety-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for clinical biomarker analysis.

Given your role managing Clinical Digital Device Solutions, I thought our Neuro-Biomarker Co-Scientist might be relevant. It uses EEG-based AI for drug responder prediction and integrates as a standardized pipeline -- designed for clinical trial settings with full on-premise deployment. It also auto-generates research briefs, which is designed to help reduce manual analysis steps for trial teams. Several Korean pharmaceutical companies use similar clinical trial pipelines with us.

I will be in Tokyo February 16-17. Would a brief conversation make sense? Happy to do Zoom as well if that works better.

Best,
Sangyoon Bae","Project Manager- Clinical Digital Device Solutions, R&D, Strategy & Operations",
Charlie Alexander,Takeda,http://www.linkedin.com/in/charlie-alexander-3693138,EN,"Hi Charlie-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We develop EEG-based AI tools for CNS biomarker analysis, deployed fully on-premise.

Takeda's plasma-derived therapy franchise is a distinctive strength, and as neurological indications increasingly intersect with immunology, I thought our Neuro-Biomarker Co-Scientist might be worth exploring. For therapies targeting neuro-immune conditions, it is designed to predict drug responders, quantify treatment effects objectively, and auto-generate standardized research briefs. Zero data leakage by design. We also support Korean pharma teams with similar neuro-biomarker workflows.

I will be in Tokyo February 16-17. Would a short conversation work? Happy to do Zoom instead if that fits your schedule better.

Best,
Sangyoon Bae","Head of Eucan, GPD and Plasma-Derived Therapy Business Development",
John Bathery,Takeda,http://www.linkedin.com/in/john-bathery-3967ab4,EN,"Hi John-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise AI tools for pharma R&D and BD operations teams.

With TAK-861's global submissions underway, I thought our Neuro-Biomarker Co-Scientist might be relevant to CNS BD operations. It provides EEG-based drug-response prediction with a standardized analysis pipeline and auto-generated research briefs -- all deployed on-premise, so data stays within your infrastructure. Designed to help reduce time spent on manual biomarker analysis for CNS programs. A number of Korean pharma BD teams use comparable analysis pipelines with us.

I will be in Tokyo February 16-17. Would a short conversation make sense? Happy to do Zoom as well if that works better.

Best,
Sangyoon Bae","Head, Business Development Operations & Externalizations - Global Business Development",
Yuki Tsushima (對馬),住友ファーマ,http://www.linkedin.com/in/yuki-tsushima-1256b9312,JA,"對馬様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。

住友ファーマ様がCNS販売部門を独立組織として維持されており、CNS領域への継続的なコミットメントに深く敬意を表しております。

CNS製剤開発においては、客観的バイオマーカーによる薬剤レスポンダーの早期特定が開発スピードを左右する重要課題かと存じます。弊社のNeuro-Biomarker Co-Scientistは、EEG基盤のAIで薬剤レスポンダーを予測し、標準化パイプラインにより客観的バイオマーカーデータを自動生成いたします。解析業務の効率化にも寄与し、オンプレミス運用でデータ管理も安心です。現在、韓国の複数の製薬企業様にも同様のオンプレミスソリューションをご導入いただいております。

2月16〜17日に東京へ伺います。ご都合の良いお時間帯をお教えいただけますでしょうか。Zoomでのご面談も可能です。

ご不要でしたらどうぞご放念くださいませ。

何卒よろしくお願い申し上げます。","Senior Director, Formulation R&D Laboratories",Japan
Yuta Shibue (渋江),住友ファーマ,http://www.linkedin.com/in/yuta-shibue-1a09072a2,JA,"渋江様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。

住友ファーマ様はオンコロジー・再生医療へのピボットを進めつつ、CNS商業基盤を維持されていると存じます。R&D戦略企画においては、客観的バイオマーカーが領域横断的な意思決定の鍵となるのではないでしょうか。

弊社のNeuro-Biomarker Co-Scientistは、EEG基盤のAIで薬剤応答を予測し、解析業務の効率化に寄与いたします。オンプレミス完全対応でデータ管理も安心です。韓国の複数の製薬企業様にも同様の臨床開発支援でご活用いただいております。

2月16〜17日に東京を訪問いたします。ご都合のよいお時間をご教示いただけますと幸いです。Zoomでも対応可能です。

ご不要でしたらどうぞご放念くださいませ。

何卒よろしくお願い申し上げます。","Senior Director, Strategy and Planning, R&D Strategy and Planning",Japan
Yusuke Sawayama (澤山),住友ファーマ,http://www.linkedin.com/in/yusuke-sawayama-b0982a184,JA,"澤山様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。

住友ファーマ様はCNS販売部門を独立組織として維持され、再生医療・オンコロジーとの戦略的バランスを図られていると存じます。グローバル経営戦略の観点から、客観的バイオマーカーは重要な意思決定ツールになり得るのではないでしょうか。

弊社のNeuro-Biomarker Co-Scientistは、EEG基盤のAIで薬剤レスポンダーを予測し、標準化パイプラインで解析業務の効率化に寄与いたします。オンプレミス対応でデータセキュリティも万全です。現在、韓国の複数の製薬企業様とも同様の評価自動化で協業を進めております。

2月16〜17日に東京へ伺います。ご面談のお時間をいただけますでしょうか。Zoomでのご説明も可能です。

ご不要でしたらどうぞご放念くださいませ。

何卒よろしくお願い申し上げます。","R&D Strategy, Global Corporate Strategy",Japan
Keita Mori,SanBio,http://www.linkedin.com/in/keita-mori-5915717,EN,"Hi Keita-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. Congratulations on the AKUUGO approval in Japan -- a meaningful milestone for CNS regenerative medicine.

As SanBio prepares for the US Phase 3 pathway, objective outcome measures will matter across regulatory environments. Our Neuro-Biomarker Co-Scientist uses EEG-based AI to predict drug responders and quantify treatment effects -- designed to help build differentiated clinical evidence. It auto-generates standardized research briefs and deploys fully on-premise with zero data leakage. We work with several Korean pharma companies on similar evidence-building workflows.

I will be in Tokyo February 16-17. Would a brief meeting work? Happy to do Zoom as well.

Best,
Sangyoon Bae","Co-CEO, Founder",
Ryohei Isobe,SanBio,http://www.linkedin.com/in/ryohei-isobe-638a76192,EN,"Hi Ryohei-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We build on-premise EEG-based AI tools for CNS clinical programs.

With AKUUGO approved in Japan and the US Phase 3 pathway confirmed with the FDA, managing biomarker data consistently across geographies becomes increasingly important. Our Neuro-Biomarker Co-Scientist is designed to provide standardized EEG analysis and auto-generated research briefs across sites, with fully on-premise deployment and zero data leakage. Could be relevant for multi-site global trial coordination for TBI programs. Several Korean pharma companies use us for similar cross-geography coordination needs.

I will be in Tokyo February 16-17. Would a short conversation make sense? Happy to do Zoom as well.

Best,
Sangyoon Bae",Senior Clinical Trial Manager,Japan
Brian Kirshner,SanBio,http://www.linkedin.com/in/brian-kirshner-931b0522,EN,"Hi Brian-san,

Thank you for connecting. I am Sangyoon Bae, Founder at RISORIUS. We develop on-premise AI tools for CNS biomarker analysis.

With AKUUGO approved in Japan and the US Phase 3 agreed with the FDA, SanBio is managing several parallel milestones. Our Neuro-Biomarker Co-Scientist is designed to help reduce time spent on manual biomarker analysis -- it uses EEG-based AI for responder prediction, provides a standardized pipeline, and auto-generates research briefs. Fully on-premise with zero data leakage. In fact, Korean pharma teams also rely on similar streamlined analysis pipelines with us.

I will be in Tokyo February 16-17. Would a short meeting work? Happy to do Zoom as well if that is easier.

Best,
Sangyoon Bae",Associate Director of Project Management,
Yuki Tanabe (田邊),EditForce,http://www.linkedin.com/in/yuki-tanabe-52b60722,JA,"田邊様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。

EditForce様のRNA編集プラットフォームは、MTPC様とのCNS契約（1.47億ドル）など、目覚ましいご実績を拝見しております。

CNS要素を持つ遺伝性疾患プログラムにおいて、客観的バイオマーカーは治療効果の客観的な評価に貢献できるのではないかと考えております。弊社のNeuro-Biomarker Co-Scientistは、EEG基盤のAIで薬剤レスポンダーを予測し、解析業務の効率化に寄与いたします。オンプレミス対応でデータ管理も安心です。韓国の複数の製薬企業様にも同様の業務支援AIでご採用いただいております。

2月16〜17日に東京へ伺います。ご都合のよいお時間をご教示いただけますでしょうか。Zoomでも対応可能です。

ご不要でしたらどうぞご放念くださいませ。

何卒よろしくお願い申し上げます。","Director, Business Development Department",Japan
Takashi Ono (小野),EditForce,http://www.linkedin.com/in/takashi-ono-0276a37,JA,"小野様

つながりをいただきありがとうございます。リソリウスのペ・サンユンと申します。

EditForce様のRNA編集技術は、MTPC様とのCNS契約（1.47億ドル）など、CNS領域で大きな成果を上げられていると拝見しております。

CNS遺伝性疾患では治療効果の客観的測定が課題です。弊社のNeuro-Biomarker Co-Scientistは、EEG基盤のAIでレスポンダー予測を行い、解析業務の効率化に寄与いたします。オンプレミス運用でデータ管理も安心です。現在、韓国の複数の製薬企業様にも同様の評価業務でご利用いただいております。

2月16〜17日に東京へ伺います。お忙しいところ恐縮ですが、ご面談のお時間を頂戴できますでしょうか。Zoomも可能です。

ご不要でしたらどうぞご放念くださいませ。

何卒よろしくお願い申し上げます。",President & Chief Executive Officer,Japan
